-transparent.png){kind=logo}
An open cross-over study of 20 patients with Parkinson's disease performed with two drugs containing L-dopa and a peripheral aromatic amino acid decarboxylase inhibitor (benserazide, carbidopa) confirmed the conclusions reached in other clinical trials that this combined treatment of Parkinson's disease is the most effective form of drug therapy available at present. With both drugs, Madopar or Sinemet, an optimum therapeutic result was obtained with relatively small doses of L-dopa (the reduction in L-dopa dosage amounting to about 80%). A loss of efficacy with both drugs, which has observed during long-term treatment of patients with Parkinson's disease, could be avoided by switching the patients from Sinemet to Madopar and vice versa. Determination of L-dopa in the plasma demonstrated that with either drug similar plasma levels of L-dopa were achieved during clinically effective treatment.
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
May 1976,
MMW, Munchener medizinische Wochenschrift,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
March 1974,
La Revue du praticien,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
January 1995,
Annals of neurology,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
March 1976,
Diseases of the nervous system,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
January 1972,
Zeitschrift fur Neurologie,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
December 1977,
Journal of neurology, neurosurgery, and psychiatry,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
August 1974,
Australian and New Zealand journal of medicine,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
December 1969,
Deutsche medizinische Wochenschrift (1946),
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
April 1979,
No to shinkei = Brain and nerve,
F Podiwinsky, and
M Mentasti, and
P Riederer, and
W Birkmayer
March 1979,
No to shinkei = Brain and nerve,
